A Prospective Cohort of Children With HIV Infection

The HIV Netherlands Australia Thailand Research Collaboration500 enrolled

Overview

To evaluate clinical and immunological outcome of children treated with HAART.

This is a long term cohort study that was started in 2002. Currently, there are 120 children enrolled in the study and are receiving HIV care according to standard practice set by the Thai Ministry of Public Health. HIV-infected parents also receive care at the same clinic.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

HIV Infections

Interventions

Zidovudine, Stavudine, Didanosine, LamivudineDRUG

Refer to the Thai guideline for HIV management 2007

Nevirapine, EfavirenzDRUG

Refer to the Thai guideline for HIV management 2007

LPV/r, Saquinavir, Indinavir, Ritonavir, NelfinavirDRUG

Refer to the Thai guideline for HIV management 2007

Eligibility

Sex: ALLMin age: 1 DayMax age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center * Children who fulfil criteria to start HAART according to the ATC program * Children who are switched to second regimen or salvage therapy * Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites) * Children with HIV infection who are not on antiretroviral therapy * Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form Exclusion Criteria: * Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.

Locations (3)

HIV-NAT

Bangkok, Thailand

Pediatric infectious diseases section, Chulalongkorn University

Bangkok, Thailand

Khon Kaen University

Khon Kaen, Thailand

Outcomes

Primary Outcomes

1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection

Time frame: every 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.